Table 4.

miRNAs involved in therapeutic response (sensitivity/resistance) in BC

Therapies	Role in response	miRNA	Putative targets	Agent	Biological samples	Refs.
Hormone therapy
Antiestrogens	Sensitivity	miR-342	CCNB1	Tamoxifen	Cell lines and tumor tissues	[149]
		miR-26a	EZH2		Tumor tissues	[150]
		miR-30c	EGFR			[147]
		miR-10, -126	–			[151]
	Resistance	miR-221/222	CDKN1B	Tamoxifen, fulvestrant	Tumor tissues and cell lines	[152, 153]
		miR-519a	CDKN1B PTEN, RB1	Tamoxifen	Tumor tissues and cell lines	[154]
		miR-155	SOCS6			[131]
		miR-210	–		Tumor tissues	[110]
		miR-301	FOXF2, BBC3, PTEN, COL2A1		Tumor tissues, cell lines and xenografts	[94]
Aromatase inhibitors	Sensitivity	miR-125b let-7c	ERBB2	Letrozole, anastrozole	Tumor tissues and cell lines	[116]
	Resistance	miR-181a	BCL2L11	Letrozole	Cell lines, xenografts and tumor tissues	[155]
Antibodies	Sensitivity	miR-210	–	Trastuzumab	Cell lines and plasma	[148]
	Resistance	miR-21	PTEN	Trastuzumab	Cell lines, xenograft and tumor tissues	[156]
Chemotherapy	Sensitivity	miR-451	MRP-1	Doxorubicin	Cell lines and tumor tissues	[157]
		miR-200c	MRP-1			[158]
		miR-134	ABCC1			[159]
		miR-128	BMI1, ABCC5	Doxorubicin, Paclitaxel	Cell lines, xenografts and tumor tissues	[121]
		miR-100	MTOR	Paclitaxel	Cell lines, xenografts and luminal tumor tissues	[119]
		miR-16	IKBKB		Cell lines and tumor tissues	[160]
		miR-621	FBXO11	Paclitaxel + Carboplatin	Cell lines, xenografts and tumor tissues	[161]
	Resistance	miR-125b	BAK1, E2F3	FEC	Cell lines, tumor tissues and serum	[162]
		miR-141	−	Taxane, Anthracyclines	Cell lines and tumor tissues	[163]
		miR-221	CDKN1B		Plasma	[164]
		miR-155	FOXO3a	Paclitaxel, VP-16, Doxorubicin	Cell lines and tumor tissues	[165]
Radiotherapy	Sensitivity	miR-155	RAD51	–	Cell lines and TNBC tissues	[166]

CCNB1 cyclin B1, EZH2 enhancer of zeste homolog 2, EGFR epidermal growth factor receptor, CDKN1B cyclin-dependent kinase inhibitor 1B, PTEN phosphatase and tensin homolog, RB1 retinoblastoma 1, SOCS6 suppressor of cytokine signaling 6, FOXF2 forkhead box F2, BBC3 BCL2 binding component 3, COL2A1 collagen type II alpha 1, ERBB2 Erb-B2 receptor tyrosine kinase 2, BCL2L11 Bcl-2-like protein 11, MRP1 multidrug resistance-associated protein 1, ABCC1 ATP binding cassette subfamily C member 1, BMI1 BMI1 polycomb ring finger oncogene, ABCC5 ATP binding cassette subfamily C member 5, MTOR mechanistic target of rapamycin, IKBKB IκB kinase β, FBXO11 F-box protein 11, BAK1 BCL2 antagonist/killer 1, E3F3 E2F transcription factor 3, FOXO3a Forkhead box O3a, RAD51 RAD51 recombinase, FEC 5-florouracil, epirubucin and cyclophosphamide